Moyamoya Disease — Research Summary
Printed from RareWays (rareways.com.au) on 11 September 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Comorbidities in sickle cell disease by age in the Indiana sickle cell data collection (IN-SCDC).
Gatz Jennifer L et al. — Hematology (Amsterdam, Netherlands) (31 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41947039/
- 2.
Preoperative ischemic territorial mismatch due to PCA involvement, postoperative STA enlargement, and transient neurological events in moyamoya disease.
Mugikura Shunji et al. — Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (1 November 2026)
https://pubmed.ncbi.nlm.nih.gov/42537508/
- 3.
Rescue direct bypass after insufficient prior revascularization in moyamoya disease: Feasibility of using reused or preserved superficial temporal artery branches.
Yamaguchi Koji et al. — Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42361714/
- 4.
Clinical and CT perfusion outcomes after direct STA-MCA bypass in moyamoya and non-moyamoya steno-occlusive disease: an Indonesian single-center cohort.
Kusdiansah Muhammad et al. — Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42385528/
- 5.
A case of anterior cranial fossa dural arteriovenous fistula concomitant with moyamoya disease.
Youda Junki et al. — Radiology case reports (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42494881/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting — Sanford Health
https://clinicaltrials.gov/study/NCT01793168
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Moyamoya Disease
Moyamoya disease is a rare condition in which the large arteries at the base of the brain slowly narrow, and a network of small, fragile vessels forms to compensate. It can cause strokes, mini-strokes and seizures in children and adults. Treatment includes surgery to improve blood flow to the brain and medicines to lower stroke risk.
Most Recent Research
OBJECTIVE: Survival for individuals with sickle cell disease (SCD) is increasing, and along with it the potential for comorbid conditions that may be caused by cumulative tissue damage. This paper examines the prevalence of comorbidities among individuals with SCD in Indiana and assesses how these vary by age group. METHODS: Data from the Indiana Sickle Cell Data Collection program (2015-2021) were used to identify confirmed and probable SCD cases. Comorbidities-asthma, avascular necrosis, stroke, retinopathy, moyamoya disease, and sickle nephropathy-were identified using ICD-9/10 codes. RESULTS: Among the 1689 individuals, the 0-17 age group was the largest (42.9%). Asthma was the most common comorbidity (23.7%), highest in the 18-39 age group. Avascular necrosis, stroke, and retinopathy increased with age, while moyamoya was most common in youth. Logistic regression showed increasing age was associated with the risk of any comorbidity risk. DISCUSSION: This study confirmed a high comorbidity burden among individuals with SCD, and that the risk of having any of the examined comorbidities increased with age. Findings align with national data, though differences in asthma and stroke prevalence highlight the impact of data sources and population characteristics. CONCLUSION: These results support the need for age-specific, multidisciplinary care strategies and provide valuable insights for clinicians, policymakers, and public health officials to improve outcomes and allocate resources effectively for the SCD population.
Common Questions
What is Moyamoya Disease?
Moyamoya disease is a rare condition in which the large arteries at the base of the brain slowly narrow, and a network of small, fragile vessels forms to compensate. It can cause strokes, mini-strokes and seizures in children and adults. Treatment includes surgery to improve blood flow to the brain and medicines to lower stroke risk.
How many clinical trials are available for Moyamoya Disease?
RareWays currently indexes 38 clinical trials for Moyamoya Disease, of which 21 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Moyamoya Disease come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Moyamoya Disease.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.